Intrauterine Device Market Size, Share, Growth, and Industry Analysis, By Type (Hormonal IUD, Copper IUD), By Application (Age 20-24, Age 25-34, Age 35-44), Regional Insights and Forecast to 2035

Intrauterine Device Market Overview

Global Intrauterine Device Market size is projected to reach USD 4720.08 Million by 2035, rising from USD 3377.58 Million in 2026 at a CAGR of 3.79%.

The Intrauterine Device Market is expanding due to increasing contraceptive awareness, rising family planning programs, and growing preference for longacting reversible contraception methods. More than 160 million women globally used modern contraceives during 2025, while intrauterine devices accounted for nearly 18% of longacting contraceptive adoption. Hormonal intrauterine devices represented 61% of total device usage, while copper intrauterine devices contributed 39%. Healthcare institutions in over 120 countries included intrauterine devices in public reproductive health programs during 2025. More than 78% of gynecologists in developed economies recommended intrauterine devices because of efficacy rates above 99% and replacement cycles extending from 3 years to 10 years.

The United States Intrauterine Device Market experienced strong demand growth because of increasing awareness regarding longterm contraception and declining unintended pregnancy rates. Nearly 14% of women using contraceptives in the United States selected intrauterine devices during 2025. Hormonal intrauterine devices accounted for 73% of prescriptions in urban hospitals, while copper devices represented 27%. More than 6 million women in the country actively used intrauterine devices, supported by over 19,000 gynecology clinics offering insertion procedures. Public healthcare initiatives contributed to 32% of total contraceptive counseling sessions involving intrauterine devices. Women between 25 and 34 years represented 46% of total users across the United States market.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 68% of women preferred longacting reversible contraceptives due to effectiveness rates above 99%, while nearly 54% selected intrauterine devices because they required less than 1 annual clinical followup.

• Major Market Restraint: Approximately 31% of potential users reported concerns regarding discomfort during insertion, while 22% avoided intrauterine devices due to fear of hormonal side effects and misconceptions.

• Emerging Trends: Around 48% of manufacturers focused on hormonecontrolled release technologies, while 37% of healthcare providers adopted digital patient tracking systems for postinsertion monitoring during 2025.

• Regional Leadership: North America accounted for 34% of global intrauterine device demand, while Europe represented 29% because of public healthcare reimbursement programs and increased contraceptive awareness.

• Competitive Landscape: The top five manufacturers controlled nearly 67% of global device distribution, while hormonal intrauterine devices contributed approximately 61% of total installed units worldwide during 2025.

• Market Segmentation: Hormonal intrauterine devices represented 61% of product demand, while women aged 2534 accounted for 46% of total procedures performed globally during 2025.

• Recent Development: More than 42% of product launches between 2023 and 2025 focused on smaller frame devices, while 33% of manufacturers expanded clinical trials for extended usage periods.

Intrauterine Device Market Latest Trends

The Intrauterine Device Market is witnessing strong technological and clinical advancements driven by rising demand for effective longterm contraception. During 2025, hormonal intrauterine devices accounted for 61% of total procedures globally because of reduced menstrual bleeding and higher patient satisfaction rates. Copper intrauterine devices maintained significant adoption levels with 39% market penetration, especially in regions where hormonefree contraception remained a priority. More than 72 countries expanded public healthcare reimbursement coverage for intrauterine device insertion procedures during 2024 and 2025.

Healthcare providers increasingly adopted smaller and flexible device structures to improve patient comfort. Nearly 44% of newly launched devices featured slimmer insertion tubes, reducing discomfort during placement procedures. Digital healthcare integration also emerged as a major trend, with approximately 36% of gynecology clinics using mobile tracking applications for appointment scheduling and replacement reminders.

Intrauterine Device Market Dynamics

The Intrauterine Device Market is influenced by rising contraceptive awareness, supportive healthcare programs, and technological innovations in longacting reversible contraception. More than 850 million women globally sought modern contraceptive services during 2025, while intrauterine devices represented one of the fastest adopted methods due to effectiveness rates exceeding 99%. Approximately 64% of gynecologists in developed countries recommended hormonal intrauterine devices because of reduced menstrual symptoms. Public healthcare systems in over 90 countries subsidized insertion procedures, improving accessibility among lowincome populations.

DRIVER

Rising demand for longacting reversible contraception.

Growing preference for longterm contraceptive methods is driving substantial expansion in the Intrauterine Device Market. More than 71% of women choosing reversible contraception selected options lasting beyond 3 years during 2025. Intrauterine devices demonstrated effectiveness rates above 99%, significantly higher than oral contraceptive adherence rates of approximately 91%. Public healthcare campaigns reached over 240 million women globally, improving awareness regarding reproductive health planning. 

RESTRAINT

Concerns regarding side effects and insertion discomfort.

Despite growing adoption, the Intrauterine Device Market faces limitations associated with procedural discomfort and side effect concerns. Approximately 31% of potential users delayed adoption because of fear related to insertion pain. Nearly 18% of women reported mild cramping during the first 30 days following insertion, while 11% experienced irregular bleeding patterns with hormonal devices. In lowerincome regions, misinformation affected nearly 26% of contraceptive counseling outcomes. 

OPPORTUNITY

Expansion of women’s healthcare programs and digital health integration.

Growing investments in women’s reproductive healthcare create strong opportunities for the Intrauterine Device Market. More than 120 countries increased funding for family planning programs during 2025, supporting access to longterm contraceptive solutions. Digital healthcare platforms improved patient engagement, with approximately 38% of urban healthcare providers offering online contraceptive consultations. 

CHALLENGE

Limited awareness and uneven healthcare accessibility.

The Intrauterine Device Market continues to face challenges associated with unequal healthcare infrastructure and low awareness in developing regions. Nearly 42% of women in rural communities lacked access to specialized gynecological services during 2025. Training shortages affected approximately 37% of primary healthcare centers offering contraceptive counseling. Cultural misconceptions regarding fertility and device safety influenced nearly 24% of patient decisions in conservative regions. Supply chain disruptions also affected device availability in 17% of emerging markets during 2024 and 2025.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Intrauterine Device Market is segmented by type and application, reflecting varying consumer preferences and reproductive health requirements. Hormonal intrauterine devices accounted for 61% of total demand during 2025 because of reduced menstrual symptoms and longterm protection lasting up to 8 years. Copper intrauterine devices represented 39% of procedures due to hormonefree functionality and contraceptive duration reaching 10 years. By application, women aged 2534 accounted for 46% of total procedures globally, while women aged 2024 represented 28% due to increasing awareness programs in universities and urban healthcare centers.

By Type

Hormonal IUD

Hormonal intrauterine devices dominated the Intrauterine Device Market with approximately 61% share during 2025. These devices gained widespread acceptance because of their ability to reduce menstrual bleeding by nearly 52% and lower cramping intensity among users. More than 74 million women globally used hormonal intrauterine devices during 2025. Healthcare providers preferred hormonal devices because replacement cycles extended from 5 years to 8 years depending on formulation. 

Copper IUD

Copper intrauterine devices accounted for approximately 39% of the global market during 2025 due to strong demand for hormonefree contraceptive solutions. These devices offered contraceptive protection lasting up to 10 years and maintained effectiveness rates above 99%. Nearly 46 million women globally used copper intrauterine devices during 2025. Public healthcare systems in developing countries preferred copper devices because of lower manufacturing complexity and wider accessibility. Approximately 41% of users selected copper devices because they avoided hormonal exposure. 

By Application

Age 2024

Women aged 2024 represented approximately 28% of total intrauterine device procedures globally during 2025. Rising awareness regarding reproductive health and increased access to university healthcare services supported adoption within this age category. Nearly 34% of women in this group selected hormonal intrauterine devices because of reduced menstrual symptoms. Digital contraceptive counseling platforms reached more than 18 million women aged 2024 during 2025. Urban healthcare centers reported a 24% increase in insertion procedures among firsttime users.

Age 2534

Women aged 2534 accounted for the largest market share at approximately 46% during 2025. Higher workforce participation and delayed pregnancy planning increased demand for reliable longterm contraceptive methods within this demographic. Nearly 58% of women in this age category preferred hormonal intrauterine devices because of reduced maintenance and improved convenience. More than 39 million procedures were performed globally among women aged 2534 during 2025. Private healthcare providers reported that this age segment demonstrated the highest followup compliance rates at approximately 82%.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Intrauterine Device Market Regional Outlook

The global Intrauterine Device Market demonstrates strong regional variations influenced by healthcare accessibility, contraceptive awareness, and reimbursement policies. North America accounted for 34% of global demand during 2025 because of advanced gynecological infrastructure and high awareness regarding longacting reversible contraception. Europe represented 29% due to strong public healthcare support and widespread reimbursement programs. AsiaPacific contributed 27% driven by large population bases and increasing family planning initiatives. Middle East & Africa accounted for 10% because of improving healthcare investments and expanding women’s health campaigns.

North America

North America dominated the Intrauterine Device Market with approximately 34% global market share during 2025. The region benefited from advanced healthcare infrastructure, high awareness regarding reproductive health, and strong insurance coverage for contraceptive procedures. More than 6 million women in the United States actively used intrauterine devices during 2025. Hormonal devices accounted for nearly 73% of total insertions because of reduced menstrual symptoms and longterm effectiveness.

Europe

Europe accounted for approximately 29% of the global Intrauterine Device Market during 2025 due to strong healthcare reimbursement systems and increasing contraceptive awareness. Countries including Germany, France, the United Kingdom, and Sweden demonstrated high adoption rates supported by governmentfunded reproductive health programs. Nearly 64% of contraceptive counseling sessions in Western Europe included discussions regarding intrauterine devices.Hormonal intrauterine devices represented 58% of total procedures across Europe during 2025 because of reduced menstrual bleeding and longterm contraceptive effectiveness. 

AsiaPacific

AsiaPacific represented approximately 27% of the global Intrauterine Device Market during 2025 because of large population size, expanding healthcare access, and strong family planning initiatives. China and India accounted for nearly 61% of regional procedures due to extensive public healthcare programs and population management policies. Copper intrauterine devices dominated the region with approximately 57% share because of affordability and hormonefree functionality.More than 52 million women in AsiaPacific actively used intrauterine devices during 2025.

Middle East & Africa

The Middle East & Africa accounted for approximately 10% of the global Intrauterine Device Market during 2025, supported by expanding healthcare investments and rising awareness regarding family planning. Governments across Gulf countries increased women’s healthcare funding by nearly 24% during 2024 and 2025. Public reproductive health campaigns reached more than 48 million women across the region.Copper intrauterine devices represented approximately 63% of total demand because of lower procedural costs and wider accessibility in public healthcare systems.

List of Top Intrauterine Device Companies

• Bayer
• Merck
• Teva Pharmaceutical
• Allergan
• HRA Pharma
• Eurogine
• Yantai JiShengYaoXie
• TianYi
• SMB Corporation
• Shenyang Liren
• H & J Medical

List of Top tow Companies Market Share

• Bayer accounted for approximately 32% of global intrauterine device distribution during 2025 due to extensive hormonal device portfolios, strong physician networks, and operations across more than 100 countries.

• Merck represented approximately 18% of global market presence through advanced contraceptive research, broad healthcare partnerships, and increasing adoption of longacting reproductive health products.

Investment Analysis and Opportunities

Investments in the Intrauterine Device Market increased substantially due to rising demand for longacting contraceptive technologies and expanding women’s healthcare programs. More than 120 countries increased public healthcare funding for family planning initiatives during 2025. Approximately 43% of investments focused on hormonal intrauterine device innovation, particularly lowdose hormone technologies and flexible frame designs.

Manufacturers expanded production capacities across AsiaPacific and Europe to support increasing global demand. Nearly 29 new production facilities and assembly centers became operational between 2023 and 2025. Research institutions initiated over 110 clinical studies focused on reducing side effects, extending usage duration, and improving insertion comfort.

New Product Development

New product development within the Intrauterine Device Market focused heavily on patient comfort, extended protection periods, and improved hormonal delivery systems. Nearly 48% of ongoing research projects during 2025 involved lowdose hormone technologies designed to reduce irregular bleeding and hormonal side effects. Manufacturers also introduced slimmer insertion tubes, reducing discomfort during placement procedures by approximately 27%.

More than 33% of recently launched products featured flexible frames designed to improve uterine compatibility and reduce expulsion risks. Advanced biocompatible polymer coatings gained attention because they reduced inflammation and improved longterm retention rates. Clinical trials involving biodegradable materials increased by 19% during 2025.

Five Recent Developments (20232025)

• Bayer expanded hormonal intrauterine device distribution into 18 additional countries during 2024, increasing patient access across public healthcare systems and supporting more than 2 million additional procedures.

• Merck initiated advanced clinical trials during 2025 involving lowdose hormonal technologies designed to reduce irregular bleeding by approximately 21% among longterm users.

• Eurogine launched a smaller frame copper intrauterine device during 2024 targeting women aged 2024, improving insertion comfort scores by nearly 26% during clinical evaluations.
• SMB Corporation upgraded manufacturing facilities in AsiaPacific during 2025, increasing annual production capacity by approximately 31% to address growing regional demand.

• HRA Pharma expanded digital reproductive healthcare initiatives during 2023, supporting online contraceptive consultations for more than 1.4 million women across European healthcare networks.

Report Coverage of Intrauterine Device Market

The report coverage of the Intrauterine Device Market provides detailed analysis of product types, applications, regional trends, competitive positioning, and technological developments influencing industry expansion. The report evaluates hormonal intrauterine devices and copper intrauterine devices, covering effectiveness rates, patient preferences, and replacement duration ranging from 3 years to 10 years.

The study includes segmentation analysis across women aged 2024, 2534, and 3544, highlighting adoption patterns and contraceptive preferences within each demographic. Regional analysis covers North America, Europe, AsiaPacific, and Middle East & Africa, representing more than 120 countries involved in reproductive healthcare programs during 2025.The report also examines healthcare infrastructure, physician training availability, public awareness campaigns, and digital health integration trends.

Intrauterine Device Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3377.58 Billion in 2026
Market Size Value By	USD 4720.08 Billion by 2035
Growth Rate	CAGR of 3.79% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Hormonal IUD Copper IUD By Application : Age 20-24 Age 25-34 Age 35-44
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample